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Background: People who inject drugs are at high risk for hepatitis B, hepatitis C and HIV. HTLV was reported by
neighboring countries to be prevalent in this population, but the situation for Germany is unclear. To generate
seroprevalence and related behavioural data and to enhance prevention efforts against these infections for drug
users in Germany, a multicentre sero- and behavioural survey was initiated. People who inject drugs are not well
reached by services for testing and counselling for blood-borne infections in Germany. An interventional part of the
study is intended to prove feasibility and acceptance of testing and counselling in low-threshold drop-in settings.
Methods/Design: Between May 2011 and March 2015, eligible participants (persons having injected drugs within the
last 12 months, aged 16 years+, and living in the study city) are recruited by respondent driven sampling, using
low-threshold drop-in facilities as study-sites in eight German cities with large drug scenes. Calculated sample size is
2,033 participants. Capillary blood samples collected as dried blood spots are anonymously tested for serological and
molecular markers of hepatitis B and C, HIV, and HTLV I and II. A detailed face-to-face-interview about hepatitis- and
HIV-related knowledge, former testing, imprisonment, sexual and injecting risk behaviour is conducted with
participants. Staff is trained to offer pre- and post-test-counselling of blood-borne infections and HIV rapid testing
to participants.
Discussion: We chose respondent driven sampling for recruitment of participants to improve representativeness of
results. Persons, who are not reached by the facility where the study is conducted, are aimed to be included by
recruitment through their personal social network of injecting drug users. To reduce differential biases in the questions
on knowledge of transmission and prevention of infections, we present true statements on hepatitis B, C and HIV, their
possible routes of transmission and measures of prevention to participants. Participants are told that the statements are
true and are asked to answer if they knew this fact already or if it is new to them. In case of knowledge gaps they are
offered free targeted counselling as well as free HIV rapid testing and post-test counselling of HIV and hepatitis test
results.
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Epidemiological situation of injecting drug users with
regards to hepatitis B, C, HIV and HTLV in Germany
Like in other Western European countries, the epidemic
of blood-borne and sexually transmitted infections in
Germany is mainly driven by transmission in vulnerable
groups. People who inject drugs (PWID) are one of the
groups most affected by hepatitis C virus (HCV) infec-
tions, but also by hepatitis B virus (HBV) infections as well
as human immunodeficiency virus (HIV), and often co-
infections with several agents occur. Furthermore, PWID
have been found to be at increased risk for infection with
the human T-lymphotropic virus (HTLV).
Hepatitis B
HBV is highly contagious and is transmitted through par-
enteral, sexual and vertical routes. Globally, around 240
million people are chronically infected with hepatitis B,
and about 600,000 people die every year due to the conse-
quences of hepatitis B. Since 1982, a safe and effective vac-
cine exists to prevent hepatitis B infection [1]. In Western
Europe, drug users are one of the key populations affected
by HBV, with prevalence of chronic infections (HBsAg
positive) ranging between 0.0% and 17.8% [2].
Germany is a country with low HBV prevalence. A re-
cent population-based survey revealed an anti-HBc anti-
body prevalence of 5.1% in the general adult population
due to former infection, and 0.3% (95% CI [0.2; 0.6])
show signs of current infection or carrier status [3].
Studies from former years indicate signs of former infec-
tion in 30–60% and low vaccination prevalence among
PWID in German cities [4,5]. Chronic HBV infection
with the potential of virus transmission is estimated to
be present in 1–7% of PWID [4,5].
Hepatitis C
HCV affects approximately 170 million people worldwide
and accounts for almost half a million deaths annually
[6,7]. Unlike most RNA viruses which usually cause acute
diseases, HCV establishes persistent infections in more
than 70% of affected persons leading to severe liver
diseases like cirrhosis and hepatocellular carcinoma.
Transmission of HCV occurs primarily via blood and
blood-contaminated objects. It is known from experimen-
tal settings, that HCV can survive drying and environmen-
tal exposure at room temperature for at least 16 hours in
infectious plasma [8]. Other studies confirmed the stability
of HCV: environmental stability in suspension with viral
infectivity was detectable for up to 28 days [9,10].
However, in small volumes of < 2 μl which are volumes
comparable with contaminated syringes, HCV remains
detectable for at least 24 hours [11].
A recent population-based survey in Germany found
a 0.3% prevalence of HCV infection in the generalpopulation [3]. Groups at increased risk like prisoners,
hospitalised persons and PWID were not included in
this survey, and migrants from regions with higher
prevalence were underrepresented. Thus it must be as-
sumed, that the true HCV prevalence is higher. Like in
other Western European countries, in Germany HCV is
hyperendemic in PWID, and regional studies found
HCV prevalence of 50–80% in this group [2,4,12-17].
Notification data reveal that in recent years most infec-
tions with information on the mode of transmission oc-
curred in PWID [18]. International studies identified
several risk factors associated with HCV infection
among PWID, such as years of injecting, sharing of nee-
dles, syringes and other equipment, HIV-co-infection
and imprisonment [13,15,19-22]. To our knowledge, in
Germany representative prevalence and associated be-
havioural data for HCV infection among PWID is miss-
ing, and it is not known to what extent co-infections
occur in this group.HIV
It is estimated that globally a total of 35,300,000 persons
were living with HIV/AIDS in 2012 [23]. In Germany, like
in other Western European countries, the HIV-epidemic is
a concentrated epidemic where sub-populations, especially
MSM are disproportionately affected [24]. The number of
persons living with HIV/AIDS in Germany was recently es-
timated to be 78,000 by the end of 2012, of whom 65% are
MSM [25]. PWID account for ~10% of infections among
people who live with the virus [25]. New HIV infections
among PWID have decreased in recent years, due to effect-
ive prevention measures like needle and syringe exchange
programs (NSP), oral opioid substitution therapy (OST)
and promotion of safer use. Among the estimated 3,400
new HIV infections in Germany in 2012, 210 (95% CI
[160–270]) were transmitted by injection drug use, corre-
sponding to 6.2% of new infections [25].HTLV
HTLV is a retrovirus. Different genotypes have been
described in humans, named 1–4. Worldwide 15 to 20
million persons are estimated to be infected with HTLV,
mainly with the genotypes 1 and 2. Endemic regions are
Japan, Western African countries, Latin America, Iran
and the Caribbean [26]. In Europe, prevalence is much
lower. Among first-time blood donors, a prevalence of
0–4.8 cases per 100.000 donors was reported for
Scandinavian countries, 4.5–4.8/100.000 for France, the
Netherlands and the United Kingdom, and 53/100.000
for Romania [27]. For many countries the epidemio-
logical situation is unknown. It is expected that immi-
gration from endemic regions may increase incidence
and prevalence in European countries.
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lymphoma and HTLV-1 associated myelopathy/tropical
spastic paraparesis. These diseases affect 3–5% of infected
individuals. Specific antiviral treatment or vaccination is
not available. HTLV is transmitted through similar trans-
mission routes as HIV, mainly via blood, sexually and from
mother-to-child by breastfeeding, and it is known that
PWID are at high risk for infection with HTLV-1 and
HTLV-2. Studies among PWID in the United States, in
Spain, Ireland and Sweden revealed high HTLV prevalence
up to 14% among PWID. [28-32] A recent sero-survey
among drug users in Sweden found a HTLV antigen preva-
lence of 3.3% [32]. In Germany, HTLV-1 and -2 prevalence
was estimated to be 0.7/10,000 pregnant women in 1997,
but current and representative data for the general popula-
tion or groups at increased risk are not available [33,34].
The European Centre for Disease Prevention and Control
(ECDC) recommends conducting HTLV sero-surveys if no
representative data is available [35].Prevention of blood-borne infections among PWID in
Germany
Interventions have been implemented in Germany, like in
other countries, to reduce the risk of acquiring blood-borne
viral infections among PWID, either by decreasing the fre-
quency of injection by OST or by reducing the risk of infec-
tion by providing sterile needles and syringes via NSP. Both
strategies have proven to be effective measures for reducing
HIV transmission, and, if combined and provided at high
coverage, as well for HCV transmission [36-39].
Another strategy implemented in recent years in some
German cities is the prescription of injectable pharmaceut-
ical diamorphine for subgroups of patients who are unable
to stop injecting opiate drugs [40]. This measure not only
serves to prevent overdose events and consequences of un-
purified drug administration, but also facilitates social re-
integration, because individuals do not need to “earn” their
daily doses of drugs by risky or criminal acts, and results in
the reduction of unsafe injections.
To monitor the impact of these programmes, it is es-
sential to analyse in detail behavioural items combined
with biological surveillance, ideally over time. By identi-
fying gaps in knowledge of transmission and prevention
of infections, as well as behaviours that favour transmis-
sion, targeted interventions may be derived from this
study.Second generation surveillance
The WHO/UNAIDS guidance on second-generation sur-
veillance for HIV infection strongly recommends the use
of behavioural surveillance in the planning and evaluation
of behavioural interventions, particularly in countries with
low-level or concentrated epidemics [41].Behavioural and socio-demographic information is es-
sential in monitoring of blood-borne infections, as trans-
mission of these infections in PWID strongly depends on
specific risk behaviour, such as sharing of injection equip-
ment and unprotected sex. These behavioural factors are
influenced by socio-economic, policy and other factors,
such as stigmatization, criminalization, marginalization,
and limited access to prevention, treatment and care. Ac-
cordingly, also socioeconomic and structural information
is important to survey in this group. Behavioural surveil-
lance focused on PWID is recommended to investigate
risk factors related to several viral infections with similar
route of transmission [42]. Ideally, this is combined with
biological data, to determine associations between risk or
preventive behaviour and infection status.
The European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) developed five key epidemio-
logical indicators to achieve its goal of providing com-
parable information on drugs and drug addiction at
European level. One of these is the drug-related infec-
tious diseases key indicator (DRID), collecting data on
the extent of infectious diseases — primarily HBV, HCV
and HIV infection — among PWID. More recently, the
collection of behavioural data as part of DRID was im-
plemented [42-44].
Respondent driven sampling
Respondent driven sampling (RDS) is a relatively new
approach to recruit hard-to-reach populations for bio-
logical and behavioural surveillance. The precondition
for using this recruitment strategy is the existence of so-
cial networks within the targeted population. Character-
istics of hard-to-reach populations are the unknown size
of the population and strong privacy concerns, because
membership to these groups often involves stigmatized
or illegal behaviour [45,46]. Among PWID, social net-
works are driven by consumption of an illicit product
and the need to maintain information about source,
price and quality. Sharing equipment is also important
for some individuals. Networks among PWID are there-
fore often well connected [46].
RDS is a modified chain-referral sampling technique,
using statistical weighting for network sizes of individuals
to generate representative estimates. Recruitment starts
with eligible and pre-selected starter persons, representing
different characteristics from the targeted population, the
so-called “seeds”. These persons are trained to recruit up
to three further persons willing to participate in the sur-
vey, and each participant will be asked to recruit further
three eligible peers for participation.
The recruitment process is supported by a coupon
system and primary and secondary incentives (for par-
ticipation and for referral of further participants). Indi-
vidual identification numbers allow for monitoring of
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cruitment waves”, the composition of the sample begins
to reach a point of “equilibrium”. The assumption is that
the final sample will be independent of the characteris-
tics of the first wave of seeds from whom recruitment
began [47].
By asking participants detailed questions about network
size and composition, statistical weights for each individ-
ual are generated. Persons with large network sizes have a
higher probability of selection into the study and are
therefore down-weighted while participants with smaller
networks receive a greater weight for analysis [47].Multiplier method for population size estimation
Estimating the population size of a hidden and hard-to-
reach population is challenging. Behaviours practiced by
injecting drug users or opioid users are illegal, and thus,
this group or other discriminated and stigmatized popula-
tions prefer not being identified or counted. Data on preva-
lence of injecting drug use in Germany are scarce, and
estimations of population size in past studies used a multi-
plier method based on treatment data, police contacts and
reported drug related deaths [48]. There are different ap-
proaches on how to estimate the prevalence of hidden and
hard-to-reach populations while using the RDS method-
ology which are either based on two or more independent
data sources. Methodologies are described in detail else-
where [49,50]. Two types of multipliers are commonly used
with RDS, the “service multiplier” and the “unique object
multiplier”. To obtain estimations on city-level, we want to
use both methods, if possible, in the respective study cities.Objectives of the study
Objectives of the survey are to determine seroprevalence
of HBV (including prevalence of vaccination acquired
antibodies), HCV, HIV and HTLV I and II among PWID
in the respective study cities and to estimate a mean sero-
prevalence for these infections among PWID in Germany.
Molecular testing aims at identifying different genotypes
of HCV and HIV among PWID in Germany. Furthermore
we want to identify behavioural determinants, risk factors
and characteristics of PWID and to evaluate knowledge
and knowledge gaps of PWID concerning these infections
and their transmission to recommend improved preven-
tion measures and interventions against these infections
among PWID. If possible, we want to estimate the preva-
lence of injecting drug use in study cities. Furthermore,
the interventional part of the study intends to prove feasi-
bility and acceptance of testing and counselling on blood-
borne infections in low-threshold settings.
This cross-sectional study is also intended to build up
a network of sites and facilities for regular monitoring of
HBV, HCV and HIV among PWID in the future.Methods/Design
Design of the study
This is a multicentre sero- and behavioural survey among
PWID using RDS. We chose “DRUCK-Study” as name for
the survey, an acronym of “Drogen und chronische Infek-
tionskrankheiten” (“Drugs and chronic infectious diseases”).
“Druck” is at the same time the slang word for “shooting a
drug”. The study is funded by the German Ministry of
Health and coordinated by the Robert Koch Institute (RKI),
which is the national public health institute with the
mandate for infectious disease surveillance and related
research.
The Federal Commissioner for Data Protection and
Freedom of Information approved the study protocol on
29/11/2012 (III-401/008#0035). Ethics approval was re-
ceived as of 19/11/2012 from the ethics committee at the
medical university of Charité, Berlin (EA4/036/11).
Selection of study cities
The survey is conducted in several large German cities with
a population of more than 500,000 inhabitants. The deci-
sion for a study site followed a list of criteria, that were col-
lected during a situation analysis, such as the presence and
size of a drug scene in the city, estimated prevalence of
injecting drug use, number of persons on OST, existence of
low-threshold facilities willing and able to participate in the
study, interest of potential cooperating partners to set up
structures for testing and counseling of infectious diseases
in drug consumption rooms or other low-threshold drop-in
facilities for injectors. Experts and representatives of these
facilities from 10 large German cities were invited to a kick-
off meeting in May 2012 to inform the coordinators at RKI
about the respective local structures and to discuss the
feasibility of conducting the DRUCK-Study. After this
meeting, the following study sites were selected: Berlin,
Essen (as pilot cities), Leipzig, Frankfurt, Cologne, Hanover,
Munich, and Hamburg (Figure 1, Table 1).
Participants and inclusion criteria
We aim to include persons older than 16 years who report
having injected drugs in the previous 12 months and con-
suming their drugs in the respective city. For participation
in the survey a person furthermore needs to be recruited
by a PWID who already participated in the study and who
gave him/her a coupon for participation. Coupons are
coded with a unique identification number and are the
only means of identification for study participants. No
other personal data allowing identification of study partici-
pants are collected. All participants have to provide writ-
ten informed consent.
Recruitment method
The RDS recruitment chains in each city are started from































Figure 1 Federal states of Germany by persons on OST per 100,000 population, and study cities. Source: Bundesinstitut für Arzneimittel
und Medizinprodukte/Bundesopiumstelle: Bericht zum Substitutionsregister 2014 http://www.bfarm.de/SharedDocs/Downloads/DE/
Bundesopiumstelle/SubstitReg/Subst_Bericht.pdf?__blob=publicationFile&v=6 (last accessed July 4th, 2014).
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facilities. Seeds are selected to cover a broad range of
PWID in the study city with respect to the following char-
acteristics: gender, age, country of origin and preferred
local drug facility in the city, reported HIV infection sta-
tus, preferred consumed drug, experience of sex work and
previous imprisonment. Furthermore, seeds should be
persons who are well connected to other eligible persons
and who are able to communicate the contents of thestudy. Seeds and all other participants receive three re-
cruitment coupons for distribution to eligible peers in
order to recruit further participants. All respondents re-
ceive EURO 10 as primary compensation for completing
the survey and possible transportation fees as well as an
additional secondary incentive (EURO 5) for each success-
fully recruited participant (up to three peers).
Depending on the estimated size of the drug scene, we
determined an expected sample size in each city.
Table 1 Characteristics of selected study cities
Berlin Essen Leipzig Frankfurt Cologne Hanover Munich Hamburg
Pop. size 2012 3.375.222 566.862 520.838 687.775 1.024.373 509.485 1.388.308 1.734.272
Estimated prevalence opioid users* 7,000 (2001) 3,000 (1998) 802" (2012) 6,000 (1998) 4,000 (1998) 3,000 (1993) 3,500 (2001) 12,000 (1993)
Number persons on OST per 100,000 pop.
(federal state) +
138 Berlin 137 North Rhine-
Westphalia




63 Bavaria 237 Hamburg
Number drug related deaths (city level) (2012) ♦ 113 20 8 21 29 3 35 49
*source: Kraus et al., 2004 [51].
‘’source: Suchtbericht der Stadt Leipzig, 2013:
http://www.leipzig.de/news/news/suchtbericht-2013-liegt-vor-alkohol-bleibt-das-grte-problem/ (last accessed July 4th, 2014).
+source: Bundesinstitut für Arzneimittel und Medizinprodukte/Bundesopiumstelle: Bericht zum Substitutionsregister 2014 http://www.bfarm.de/SharedDocs/Downloads/DE/Bundesopiumstelle/SubstitReg/Subst_Bericht.
pdf?__blob=publicationFile&v=6 (last accessed July 4th, 2014).
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pected sample size is reached or at a pre-determined
date, after 8 to 10 weeks, depending on opening hours
and feasibility at the study site. Low-threshold drop-in
facilities in each study city serve as study sites, and the
study operating hours are usually outside the regular
opening hours of the facility to avoid solely recruiting
regular clients of the facility.
Indicators, questionnaire development and behavioural
data
The study was implemented to capture a broad range of
indicators in order to compare German data with other
countries and PWID with other (vulnerable) populations.Table 2 Indicators by ECDC, EMCDDA and GARP/UNGASS pro
Contextual indicators
Highest level of education




Knowledge about HIV/AIDS and/or treatment
Awareness of prevention activities
PWID specific indicators
**Sharing needles/syringes in last 4 weeks (includes both lending and borrow
**Sharing of any injecting paraphernalia in last 4 weeks excluding needles/sy
as well as otherwise; only current IDUs)
**Recent HCV testing uptake (ever and in last 12 months)
Injecting frequency in last 4 weeks
Number of different sharing partners (in last 4 weeks; only sharing needles/sy
Number of sterile needles/syringes for personal use in last 4 weeks
Opioid maintenance treatment
Years since first injection
Ever injected in prison
Types of drugs consumed
Health status and health care access/usage
General indicators for STI surveillance common to all populations
Number of sexual partners in last 12 months
Condom use at last intercourse (in last 12 months)
Condom use at last intercourse (in last 12 months) with identification of type
**Ever and recent HIV-testing uptake (in last 12 months)
Result of last HIV test (reported or measured)
Having paid for sex in last 12 m
Having been paid for sex/anal/vaginal sex to clients for money, drugs or oth
Use of condom at last paid intercourse (in last 12 months)
**EMCDDA core indicator.The EMCDDA provides a model questionnaire to respond
to a list of core -, additional - and optional indicators in
sero-behavioural surveys for drug-related infectious dis-
eases among PWID. Furthermore, we aimed to be able to
derive data for reporting of the Global AIDS response pro-
gress (GARP)/United Nations General Assembly Special
Session on HIV/AIDS (UNGASS) and provide indicators
used by ECDC. A list of indicators that are covered with
this survey is shown in Table 2.
The initial questionnaire for the pilot study in Berlin was
developed following the recommendations of EMCDDA,
and – in co-operation with the Berlin-based low-threshold
facility Fixpunkt e.V. and Deutsche AIDS-Hilfe e.V. -
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ies to ensure validity and reliability before it was used in the
main study. The final questionnaire consists of 114 ques-
tions and 26 knowledge items. The questions are classified
into 13 chapters on socio-demography, personal network,
injecting history, consumption patterns, sharing of injection
and drug preparation equipment, OST, sexual risks, im-
prisonment, testing history and reported HBV-, HCV- and
HIV-status, health status, overdose history, sources of in-
formation and knowledge on infections and their trans-
mission. The latter are presented to participants as true
statements concerning transmission and prevention of
HBV, HCV and HIV, and are introduced as such by the
interviewer. The participant has to answer whether he/she
‘knew this already’, ‘didn’t know exactly’ or ‘didn’t know’.
Interviewers are trained not to intervene or to give expla-
nations during the interview, if participants have know-
ledge gaps. Instead the interviewer should mark the
respective statement and offer targeted counseling in these
areas by a trained test-counselor after the interview, even
if test results are not requested by the person.
Biological data collection and laboratory testing
Capillary blood samples are collected by a trained lab
technician from each participant by finger prick. Blood
drops are then spotted on filter cards with 10 partially pre-
punched disks (Whatman 903, GE Healthcare Life Sci-
ences, Freiburg, Germany) to prepare dried blood spots.
From each person a minimum of six blood spots of ~ 30 µl
is needed. Filters have to dry for at least three hours or
overnight at room temperature. They are then sent to the
laboratory in zip-locked plastic bags together with desic-
cants via regular mail. Every DBS filter card, already labeled
with the unique identifier, is marked with a lab identifier,
which is entered into the lab database. Upon receiving the
filter cards at the laboratory, filter disks are fully broken
out, transferred to reaction tubes and stored away at -20°C
until testing. Antibodies are eluted from the DBS in phos-
phate buffered saline supplemented with 0.05% Tween 20,
3% new born calf serum at a dilution of maximally 1:15
with respect to the blood volume dried down.
DBS testing for this study has been validated during the
pilot study in 2011 by the Institute of Virology, National
Reference Centre for Hepatitis C, at University of
Duisburg-Essen, Essen. During this period, all serological
tests were performed on the ARCHITECT system (Abbott
Diagnostics, Delkenheim, Germany). For molecular ana-
lyses, the artus HBV LC PCR (Qiagen, Hilden, Germany)
and the VERSANT HCV RNA qualitative (TMA, Siemens
Healthcare Diagnostics, Eschborn, Germany) assays were
used, respectively. The salient results of this validation are
described in detail elsewhere [52]. The Institute of
Virology, University of Duisburg-Essen, performed all
tests during the first two pilots in Berlin and Essen, in2011. Since 2012, for the remaining six cities testing is
performed in the Department for Infectious Diseases at
RKI, for HIV and HTLV in the Division for HIV and other
Retroviruses, for HBV and HCV in the Division for Viral
Gastroenteritis and Hepatitis Pathogens and Enterovi-
ruses. The protocol has since been moderately modified
and was therefore re-validated. We validated commercially
available EIA (Monolisa) and recombinant immunoblot
(recomLine) test kits using various HBV and HCV positive
serum samples and additionally 35 serum, plasma, and
DBS samples of the study population drawn in parallel.
For anti-HCV EIA and immunoblot the data showed that
2/35 (5.71%) samples differ in DBS (were negative) in con-
trast to the serum and plasma samples (were positive)
while the immunoblot confirmed the serum/plasma re-
sults. Comparison of anti-HBc results showed 2/35
(5.71%) differences between DBS and serum/plasma sam-
ples. However, the analysis of anti-HBs antibody detection
in DBS, serum and plasma revealed differences of 7/35
(20%) between DBS and serum/plasma. The seven anti-
HBs negative DBS were all at the detection limit of the
EIA for DBS showing very low anti-HBs antibody concen-
trations of <100 U/l.
Serological testing and molecular genome detection by
(RT)-PCR techniques for HBV and HCV
For the detection of anti-HCV antibodies the Architect
anti-HCV (during the pilot study) and the Monolisa Anti-
HCV Plus Version 2 (Bio-Rad, Hercules, USA) assays are
used. To confirm anti-HCV EIA-positive results respective
samples are additionally tested using the recomLine HCV
IgG strip-immunoassay (Mikrogen, Neuried, Germany).
The anti-HCV test systems are performed strictly as rec-
ommended by the manufacturers.
Serological detection of anti-HBs and anti-HBc anti-
bodies is performed using commercial available EIAs
according to the manufacturer’s instruction. For (semi)-
quantitative determination of anti-HBs antibodies the
ARCHITECT anti-HBs (during the pilot study) and the
Monolisa Anti-HBs Plus assays (Bio-Rad, Hercules,
USA) are used. Qualitative anti-HBc detection was per-
formed by ARCHITECT anti-HBc asay during the pilot
study and since 2012 by the Monolisa Anti-HBc Plus
assay (Bio-Rad, Hercules, USA). Isolated positive anti-
HBs results without any additional positive serological
and molecular HBV diagnosis argue for a successful
previous HBV vaccination.
Nucleic acids are extracted from the DBS following
the protocol as described [53,54] or using the Nucli-
SENS® miniMAG® platform and the corresponding
Magnetic Extraction Reagents (BioMérieux, Boxtel,
Netherlands) according to the manufacturer’s protocol.
Extracted and purified viral nucleic acid is stored at -80°C
until use. Sample processing (DNA/RNA extraction,
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are done in separate laboratory rooms, which are all certi-
fied for molecular diagnostics using standard precautions
to prevent assay contamination.
For detection of HBV DNA during the pilot study, the
artus HBV LC PCR assay was used. Since 2012, detec-
tion of all HBV genotypes (A-H) is performed as de-
scribed previously [52,55] with minor modifications. In
brief, extracted nucleic acids and the primers HBV-22,
HBV-65, and HBV-66 were used to amplify a 408 bp re-
gion of the preS/S-region of the HBV genome. For the
second round the primer pair HBV-24, HBV-41, and
HBV-64 are used. PCR run is performed as described
previously [55]. Lower detection limit for HBV genome
detection is 100 IU/ml in DBS.
Detection of HCV genomes was performed using the
VERSANT HCV RNA qualitative (TMA) assay (during
the pilot study) and since 2012, a one-step RT-PCR tech-
nique (Qiagen, Hilden, Germany). The RT-PCR method
amplified a 262 bp region of the 5′-NCR domain of the
HCV genome. Pre-denaturation is performed at 50°C for
30 minutes and followed by 95°C for 15 minutes. The
PCR amplification is for 40 cycles including: denaturing
at 94°C for 30 seconds, annealing at 54°C for 30 seconds,
extending at 72°C for 45 seconds and followed by a final
extension for 10 min at 72°C. The nested PCR is initi-
ated by a denaturation step at 95°C for 15 min and 35 cy-
cles at 94°C for 30 seconds, 58°C for 30 seconds, 72°C
for 45 seconds and followed by a final extension for
5 min at 72°C. Lower detection limit for HCV genome
detection is 1 × 103 IU/ml in DBS.
All test results are transferred into the study database
and forwarded to the coordinators, provided with inter-
pretation and diagnosis. Diagnoses of HCV and HBV re-
sults are made according to the German guidelines for the
Prophylaxis, Diagnosis and Therapy of HCV [56] and
HBV [51,57].
Genotyping of HBV and HCV
Since 2012, for sequencing, the RT-PCR products are
purified by Exo SAP-IT kit (USB Corporation, Ohio,
USA) according to the manufacturer’s instruction. Se-
quencing reactions are performed using 1–5 μl purified
PCR products and 0.5 μM of the primers HCV-240 and
HCV-235 for HCV genotyping and the primers HBV-24
and HBV-41 for HBV genotyping. Sequencing results
are analysed using BioEdit 9.7 software (http://www.
mbio.ncsu.edu/BioEdit/bioedit.html) and Geneious Pro
(Version 5.5.7, Biomatters Ltd, Auckland, New Zealand,
http://www.geneious.com). The phylogenetic recon-
struction of DNA sequences is carried out by MEGA 5
software [58]. For alignment and HBV- and HCV-
genotyping, prototype HBV- and HCV-genotype se-
quences retrieved from the NCBI Gene bank are used.Serological testing for HIV and HTLV and molecular testing
for HIV
HIV-1/-2 antibodies are screened with the ARCHITECT
HIV Ag/Ab combo assay (during the pilot study) and
since 2012, with the 3rd generation Murex HIV 1.2.O
ELISA (DiaSorin) and Genscreen HIV 1.2.O ELISA
(Bio-Rad Laboratories GmbH) according to the manu-
facturer’s instructions. Samples reactive in both ELISAs
are analysed by the immunoblot HIV Blot 2.2 (MP Diag-
nostics, DiaSorin). If HIV-2 antibodies are suspected
(presence of indicator band) the HIV-2 specific NEW
LAV Blot 2 (Bio-Rad) is performed. Evaluation of the
immunoblot results is performed according to the man-
ufacturer’s instructions.
HTLV-1/2 antibodies are screened using the Murex
HTLV1 + 2 ELISA (DiaSorin). Reactive samples are con-
firmed by HTLV Blot 2.4 (MP Diagnostics, DiaSorin).
An external HIV and HTLV-1 positive control (Dried
Plasma Spot) is used in each test run in addition to the
internal test controls.
HIV molecular testing is performed for confirmed posi-
tive HIV-1 samples. HIV-1 RNA is extracted as described
above. HIV-1 viral load is determined by an inhouse quan-
titative real time TaqMan LTR-RT-PCR (101 bp fragment
of the HIV-1 LTR, HXB2 Acc. No. #K03455, coordinates
542–641) using 67 μl plasma equivalent input RNA. Filter
dried serial dilutions of HTLVIIIB in HIV negative human
plasma are used as concentration standard. The lower
limit of quantification for HIV-1-RNA from DBS is 650
copies/ml. Samples with viral loads ≥6500 copies/ml are
analysed using the ViroSeq HIV-1 genotyping system (Ab-
bott, Wiesbaden, Germany) to amplify and sequence the
viral protease and partial reverse transcriptase. Subtyping
is performed using the REGA subtyping tool (http://
dbpartners.stanford.edu:8080/RegaSubtyping/stanford-
hiv/typingtool, version 3).
Study flow and training of study staff
Before starting the survey in each city a two-day training
workshop is held where staff is trained for the different
core functions in the study: a coupon manager is trained
to screen for inclusion criteria, to prevent multiple enrol-
ment of PWID, to provide a unique identification number
to each participant and to document the recruitment
chains, to explain the recruitment process to participants,
to provide them with numbered coupons for further re-
cruitment and to pay out primary and secondary incen-
tives. Interviewers learn to conduct the questionnaire-
assisted interview via intensive face-to-face training and to
offer counselling by a trained person in case of knowledge
gaps. We trained the counsellors to provide voluntary
counselling for viral hepatitis and HIV (rapid testing). A
laboratory person is qualified to perform HIV rapid test-
ing with the Vikia HIV 1/2 (Biomérieux) from capillary
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cards. A medical doctor is trained in post-test counsel-
ling. At each study site a study site manager is trained
to overview the study flow, to manage adverse events
and to inform participants of the contents of the study
and to obtain their consent.
PWID coming with a valid coupon for study participa-
tion are first screened for inclusion criteria. Eligible par-
ticipants are then informed about the objectives and
contents of the survey: every participant has to undergo
a detailed face-to-face interview and provide a capillary
blood sample. Furthermore participants are offered vol-
untary counselling on HIV and viral hepatitis, anonym-
ous HIV rapid testing, and they can request their HCV
and HIV test results from DBS. After giving written in-
formed consent, the participants receive the study docu-
ments marked by a unique numeric identifier and are
then interviewed. The interviewer asks the participant if
she/he wants to receive test results and whether an-
onymous HIV rapid testing is requested, and if yes, the
person undergoes pre-test-counselling. In case of know-
ledge gaps during the interview the interviewer offers
targeted counselling by trained staff to the participant. If
the respondent does not want to receive test results or
targeted counselling, she/he goes directly to the lab
technician for finger prick. If requested, at that occasion
the HIV rapid test is performed in supplement to the ca-
pillary blood sample. Study participation is completed
after the capillary blood sample is taken. The participant
hereafter returns to the coupon manager to receive the
primary incentive. Furthermore, the coupon manager ex-
plains how to recruit up to three other persons forFigure 2 Overview of the study flow.participation in the study and provides the participant
with three numbered recruitment coupons.
If the participant has had rapid testing for HIV with a
reactive test result, a venous blood sample is taken for
confirmatory testing in the laboratory. In that case, the
participant has to come back after two weeks to receive
the final result, as well as for HCV and HIV test results
provided by DBS. Test results of rapid and DBS testing
are generally given back to the participants by a medical
doctor. Persons with newly diagnosed infections are re-
ferred to infectious disease specialists for confirmation
of the test result by a venous blood sample and further
medical care. An overview of study flow is shown in
Figure 2.
Sample size
We want to recruit current injectors in eight large German
cities. Sample size was calculated on the basis of the infec-
tion with the lowest estimated prevalence (HIV). To our
knowledge, estimates for HTLV I and II prevalence among
German PWID are not available. Prevalence of HIV among
PWID is expected to be 4%. The sample size should be
large enough to ensure that if the true prevalence is 4%, the
95% CI of the resulting prevalence estimate should be in-
cluded in the interval 2.5% to 5.5% with a probability of
90%. In case the true prevalence is 5%, we want the 95%
confidence interval of the resulting prevalence estimate to
be included in the interval 3.5% to 7.0% with a probability
of 90%. To ensure this we need a sample size of 2,033
PWID.
We assume that the data of the different cities can be
pooled for the estimation of a general HIV prevalence.
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per city, depending on the size of the respective drug
scene.
Data analysis
Data is double entered, using EpiData 3.1. RDS weights
and 95% confidence intervals for sociodemographic fac-
tors and factors associated with infection are generated,
using the RDS analysis tool (RDSAT Version 7.1) [53].
Frequency distributions will be tabulated for all vari-
ables, performing range checks and cross-validations.
Characteristics of the study population will be described
precisely, using RDSAT-generated weights for bivariate
analysis, for the whole sample, but also for each study
city separately. Multivariate logistic regression will be
used to explore the associations between outcome vari-
ables such as RDSAT-generated weighted status of infec-
tion and vaccination, and risk- or protective factors such
as opioid substitution treatment, drug consumption
patterns, sharing of equipment, injecting in prison,
unprotected sex, and socio-demographic factors (like
educational level, living status, job situation). All ana-
lyses will be conducted using RDSAT Version 7.1 and
the statistical software Stata, version 12.
Discussion
Choice of the RDS sampling strategy
Former studies among drug users in Germany were con-
ducted as convenience sample in drug consumption facil-
ities, or among persons in OST-facilities or detoxification
units [4,12-14,54,59]. We aimed to reach a more represen-
tative sample of the whole drug scene in a city and chose
RDS, because this method claims to achieve representa-
tiveness. PWID are known to be a well-networked group,
and RDS proved to be an effective method to rapidly re-
cruit PWID [46,50,60,61]. A long recruitment process over
months would not be feasible in most study sites. Further-
more, RDS makes it possible to recruit PWID who might
not be reached by the existing low-threshold facilities in
the study cities and thus can only be reached by their per-
sonal social network. Collecting information about the
PWID currently not reached is vital for improving local
prevention efforts as well as for the planning of future
regular monitoring of HBV, HCV and HIV among PWID
by using data collected through these facilities.
Asking questions on knowledge
Initially, in the pilot cities, the knowledge section of the
questionnaire was designed questions on transmission
and prevention of HBV, HCV and HIV with true and
false response options that participants had to choose.
Due to concerns about interviewer bias as well as for
ethical considerations - realising that the knowledge
questions presented an opportunity of learning for theparticipants - the design was changed. After discussion
with experts during the kick-off-meeting of this study in
May 2012, true statements concerning transmission, pre-
vention, treatment and general characteristics of HBV,
HCV and HIV are presented to participants. By provid-
ing true statements, and also introducing them as such,
participants now have the opportunity to learn some-
thing while completing the interview. In case of know-
ledge gaps, participants are offered to see a counsellor,
even if test results are not requested by the person.
Learning facts about transmission and prevention of
blood-borne viral diseases during the interview and be-
ing counselled in case of knowledge gaps is one of the
interventional parts of the DRUCK-study. First experi-
ences with this kind of knowledge statements prove
feasible and well-accepted by both study staff and
participants.Pre- and post-test counselling in low-threshold drug
facilities
Until now, voluntary counselling and testing (VCT) for
blood-borne viruses in Germany is mainly offered by
medical doctors, substitution therapy specialists, and by
some local health departments (anonymously and free of
charge). Due to the illicit nature of drug consumption,
PWID are not well reached by these services. A pilot
project offering anonymous HIV rapid testing and coun-
selling in some German drop-in-facilities showed that
this group was reached successfully [62].
We conduct this survey in low-threshold drug facil-
ities, where VCT for HBV, HCV and HIV was rarely
available before. Before starting recruitment, staff is
trained for all VCT procedures. Counselling follows
international recommendations and the German recom-
mendations provided by Deutsche AIDS-Hilfe [63]. If
well-accepted during the study by both, staff and injec-
tors, implementation of a regular VCT offer and of
rapid testing in the facility may be eased.Challenges and limitations
There are a number of important challenges and limita-
tions preexisting when designing the study. PWID are a
stigmatized, hard-to reach population. Although all data
is anonymised, and no personal information is collected
from study participants, participants might have difficul-
ties in reporting sensitive data such as unsafe use and
sexual behaviours, imprisonment or testing history. We
try to limit the reporting bias of sensitive data by choos-
ing interviewers who are familiar to most of the local
PWID (e.g. social workers or volunteers working at the
local facilities). Behavioural surveys cannot take place
without the informed consent of the respondent. How-
ever, signing a form might inhibit the feeling of
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sent to the study site manager, if written consent is
refused.
Another issue concerns the question of true answers in
self-reported behavioural data due to social desirability, and
also of accuracy in items with 12 months recall periods.
Furthermore, potential selection bias might be a prob-
lem in our study population. Experience has shown that
respondents are more likely to refuse to participate if
they are asked to provide a specimen for testing [41].
Reaching the targeted sub-sample size for the respective
study cities depends on many factors and might not be
possible for each city. To reach the targeted total sample
size (2,033), it might be necessary to conduct the study
in an additional city.
In chronic infections like HBV, HCV and HIV infections
it is not possible to draw direct associations between be-
havioural items and time of acquisition of infection. We
can only identify associations between the status “infected”
or “not infected” and risk and preventive behaviours re-
ported for a certain time period in the past. In case an in-
fection was newly diagnosed in the study we may assume
that the same behaviour caused infection. If an infection
was known already by the participant, direction of cause
and effect could be both ways.
Because of the cross-sectional nature of this survey,
we will be unable to infer direct causal relationships be-
tween socio-demographic and behavioural factors or the
impact of prevention programs on behaviour change.
Moreover, a change of laboratory methodologies could
limit direct comparison of test results of the two pilot
cities and the remaining six cities. The dilution of the
original sample volume during elution from the filter
disk was 1:10 for the first two cities and then increased
to maximally 1:15 for the following six cities to allow re-
peated testing of samples. With respect to HIV serology,
established HIV infections are detected at comparable
sensitivity by the two assays, however, individuals in a
very early seroconversion stage could be missed by third
generation EIA [50% of samples in seroconversion (re-
active EIA/indeterminate immunoblot] resulted in false-
negative immunoblot results, but still showing reactive/
indeterminate ELISA]. The prevalence of HIV could
therefore be slightly underestimated in 6/8 cities, but
seroconverters are expected to represent only a very
small fraction of the study participants.
We furthermore had to modify the anti-HBV and anti-
HCV antibodies test systems after the pilot study. All
methodologies were validated, but direct comparison be-
tween study sites has to be done with caution. Assess-
ment of all serological test systems for HBV and HCV
shows good accordance between directly tested serum
samples in comparison to DBS except for anti-HBs in
weakly positive sera. Weakly anti-HBs positive samplescould be missed with this procedure. Thus the preva-
lence of anti-HBs antibodies, e.g. of HBV vaccinated
individuals, based on the DBS technique, must be con-
sidered as minimal estimate. However, the anti-HCV
and anti-HBc results demonstrate high accuracy of our
test systems and yielded comparable validation results.
This is the first sero-behavioural survey among current
injectors in Germany aiming to collect representative
data on blood-borne viral infections in several cities in
over 20 years. Knowledge from behavioural, serological
and molecular testing data will help to focus prevention
strategies. Depending on the outcomes, we will recom-
mend conducting similar surveys in regular intervals, to
monitor changes in behaviour and prevalence over time
and assess outcomes of adapted preventive measures.
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